← Back to Search

Lymph Node Mapping in Patients With Endometrial Cancer

N/A

Waitlist Available

Led By Floor Backes, MD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up average of 1-14 days after the procedure when final pathologic evalulation has been completed

Awards & highlights

Approved for 10 Other Conditions

No Placebo-Only Group

Summary

This clinical trial studies lymph node mapping in patients with endometrial cancer. Lymph node mapping may allow for limited removal of lymph nodes in as part of endometrial cancer staging and treatment.

Eligible Conditions

Endometrial Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ average of 1-14 days after the procedure when final pathologic evaluation has been completed

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~average of 1-14 days after the procedure when final pathologic evaluation has been completed

This trial's timeline: 3 weeks for screening, Varies for treatment, and average of 1-14 days after the procedure when final pathologic evaluation has been completed for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease

Secondary study objectives

Percentage of Metastatic Cases Found Using Ultra-sectioning and IHC Staining

Awards & Highlights

Approved for 10 Other Conditions

This treatment demonstrated efficacy for 10 other conditions.

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: sentinel lymph node detectionExperimental Treatment4 Interventions

Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

sentinel lymph node detection

2013

N/A

~210

Indocyanine green

FDA approved

Isosulfan blue

FDA approved